Terms: = Skin cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
491 results:
1. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced nras-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract] [Full Text] [Related]
3. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in nras/MAPK-driven melanoma.
Feichtenschlager V; Chen L; Zheng YJ; Ho W; Sanlorenzo M; Vujic I; Fewings E; Lee A; Chen C; Callanan C; Lin K; Qu T; Hohlova D; Vujic M; Hwang Y; Lai K; Chen S; Nguyen T; Muñoz DP; Kohwi Y; Posch C; Daud A; Rappersberger K; Kohwi-Shigematsu T; Coppé JP; Ortiz-Urda S
Mol Cancer; 2024 Feb; 23(1):40. PubMed ID: 38383439
[TBL] [Abstract] [Full Text] [Related]
4. HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker.
Amrane K; Le Meur C; Besse B; Hemon P; Le Noac'h P; Pradier O; Berthou C; Abgral R; Uguen A
Front Immunol; 2023; 14():1285895. PubMed ID: 38299143
[TBL] [Abstract] [Full Text] [Related]
5. Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report.
Shahab SW; Patil P; Fangusaro JR; Patteson B; Goldman-Yassen A; Eaton BR; Boydston W; Schniederjan M; Aguilera D
Curr Oncol; 2024 Jan; 31(1):579-587. PubMed ID: 38275834
[TBL] [Abstract] [Full Text] [Related]
6. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.
Meraz-Torres F; Niessner H; Plöger S; Riel S; Schörg B; Casadei N; Kneilling M; Schaller M; Flatz L; Macek B; Eigentler T; Rieß O; Garbe C; Amaral T; Sinnberg T
J Exp Clin Cancer Res; 2024 Jan; 43(1):30. PubMed ID: 38263136
[TBL] [Abstract] [Full Text] [Related]
7. Missense mutation of nras is associated with malignant progression in neurocutaneous melanosis.
Takahashi H; Natsumeda M; Hara N; Koyama A; Shimizu H; Miyashita A; Satake D; Mouri Y; Tsukano J; Kawabe K; Tsukamoto Y; Okada M; Ogura R; Yuki A; Umezu H; Kakita A; Ikeuchi T; Oishi M
Acta Neuropathol Commun; 2024 Jan; 12(1):14. PubMed ID: 38254245
[TBL] [Abstract] [Full Text] [Related]
8. Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: A rare but fatal condition.
Abele M; Forchhammer S; Eigentler TK; Popescu A; Maschke L; Lohse J; Lehrnbecher T; Behnisch W; Groll AH; Jakob M; Bernbeck B; Brecht IB; Schneider DT
Pediatr Blood Cancer; 2024 Apr; 71(4):e30859. PubMed ID: 38225622
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian cancer Centres.
Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
[TBL] [Abstract] [Full Text] [Related]
11. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in nras-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
[TBL] [Abstract] [Full Text] [Related]
12. A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal cancer.
Lee KW; Han SW; Kim TW; Ahn JB; Baek JY; Cho SH; Lee H; Kim JW; Kim JW; Kim TY; Hong YS; Beom SH; Cha Y; Choi Y; Kim S; Bang YJ
Cancer Res Treat; 2024 Apr; 56(2):590-601. PubMed ID: 38062706
[TBL] [Abstract] [Full Text] [Related]
13. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
[TBL] [Abstract] [Full Text] [Related]
14. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
[No Abstract] [Full Text] [Related]
15. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent nras and CTNNB1 mutations.
Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
[TBL] [Abstract] [Full Text] [Related]
16. Mucosal Melanoma: Epidemiology, Clinical Features, and treatment.
Sergi MC; Filoni E; Triggiano G; Cazzato G; Internò V; Porta C; Tucci M
Curr Oncol Rep; 2023 Nov; 25(11):1247-1258. PubMed ID: 37773078
[TBL] [Abstract] [Full Text] [Related]
17. Association of nras mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.
Mo Z; Liu J; Zhang J; Deng Y; Xu M; Jiang Y
Int Immunopharmacol; 2023 Nov; 124(Pt B):110973. PubMed ID: 37769536
[TBL] [Abstract] [Full Text] [Related]
18. Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition.
Martin SB; Polubothu S; Bruzos AL; Kelly G; Horswell S; Sauvadet A; Bryant D; Zecchin D; Riachi M; Michailidis F; Sadri A; Muwanga-Nanyonjo N; Lopez-Balboa P; Knöpfel N; Bulstrode N; Pittman A; Yeh I; Kinsler VA
J Invest Dermatol; 2024 Mar; 144(3):593-600.e7. PubMed ID: 37716647
[TBL] [Abstract] [Full Text] [Related]
19. Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
Znaider VK; Mikkelsen LH; Jensen CFS; Sønksen J; Heegaard S
Scand J Urol; 2023 Aug; 58():52-59. PubMed ID: 37635444
[TBL] [Abstract] [Full Text] [Related]
20. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
[Next]
